Byonanebye et al., Hypertension artérielle et inhibiteurs d’intégrase chez les personnes vivant avec le VIH
Hypertension artérielle et inhibiteurs d’intégrase chez les personnes vivant avec le VIH. HIV Medicine L’hypertension artérielle est l’une des principales causes de décès prématuré dans le monde et constitue un problème croissant chez les personnes vivant avec le VIH. Environ un tiers des adultes vivant avec le VIH dans le monde souffrent d’hypertension. Il existe […]
Chalouni et al., Impact of hepatitis C cure in PWH
Impact of hepatitis C cure on risk of mortality and morbidity in people with HIV after antiretroviral therapy initiation. AIDS Chalouni et al. for the Antiretroviral Therapy Cohort Collaboration (ART-CC) aimed to assess the risks of overall mortality, AIDS-defining events, and non-AIDS-defining nonliver-related (NANL) cancers between hepatitis C virus (HCV-) co-infected people with HIV (PWH) […]
Zeeb et al., HIV and tuberculosis in Switzerland
Understanding the decline of incident, active tuberculosis in people with HIV in Switzerland. Clinical Infectious Disease Zeeb et al. conducted a comprehensive study to evaluate trends of incident tuberculosis (TB) and its association with HIV viral suppression among people with HIV (PWH) in the Swiss HIV Cohort Study (SHCS). In addition, the study assessed the […]
Álvarez et al., Determinants of HIV virological outcomes
Plasma HIV-1 RNA and CD4+ T-cell counts are determinants of virological non-suppression outcomes with initial integrase inhibitor-based regimens: A prospective RESPOND cohort study. Clinical Infectious Diseases Álvarez et al. for the RESPOND (International Cohort Consortium of Infectious Diseases) Study Group aimed to examine baseline factors associated with virological nonsuppression outcomes (blips, low-level viremia [LLV], […]
Surial et al., INST and CVD events after starting ART
Impact of integrase inhibitors on cardiovascular disease events in people with human immunodeficiency virus starting antiretroviral therapy. Clinical Infectious Diseases Surial et al. performed a target trial emulation to examine the effect of starting integrase inhibitor (INSTI) based antiretroviral therapy (ART) compared to other ART combinations on cardiovascular disease (CVD) events among treatment-naïve participants in […]
Thoueille et al., Tenofovir population pharmacokinetics
Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration. Journal of Antimicrobial Chemotherapy Thoueille et al. aimed to describe tenofovir pharmacokinetics (PK) and its variability in people living with HIV (PLWH) under tenofovir alafenamide in a real-life setting. The authors conducted a population PK analysis […]
Griessbach et al., Antibody response after third vaccination with mRNA-1273 or BNT162b2
Antibody response after third vaccination with mRNA-1273 or BNT162b2: Extension of a randomized controlled SARS-CoV-2 noninferiority vaccine trial in patients with different levels of Immunosuppression (COVERALL-2). Open Forum Infectious Diseases In this randomized trial, nested within the Swiss HIV Cohort (SHCS) and the Swiss Transplant Cohort Study (STCS), Griessbach et al. compared the antibody responses […]
Speich et al., Risposta anticorpale in persone immunocompromesse dopo la vaccinazione contro COVID-19
Risposta anticorpale in persone immunocompromesse dopo la vaccinazione contro COVID-19 con i vaccini di Pfizer-BioNTech e Moderna. Clinical Infectious Diseases In Svizzera, i due vaccini COVID-19 di Pfizer-BioNTech e Moderna sono stati autorizzati nel dicembre 2020 e nel gennaio 2021. Entrambi i vaccini sono stati testati in studi di autorizzazione che hanno coinvolto decine […]
Speich et al., Antikörperreaktion bei immungeschwächten Personen nach COVID-19 Impfung
Antikörperreaktion bei immungeschwächten Personen nach COVID-19 Impfung mit Pfizer-BioNTech und Moderna Impfung. Clinical Infectious Diseases In der Schweiz wurden die beiden COVID-19 Impfstoffe von Pfizer-BioNTech und Moderna im Dezember 2020 und Januar 2021 zugelassen. Beide Impfungen wurden in Zulassungsstudien mit mehreren zehntausend Teilnehmenden getestet. Basierend auf diesen Studien wurden die Impfungen als sicher und […]
Speich et al., Réaction d’anticorps chez des personnes immunodéprimées après vaccination contre le COVID-19
Réaction d’anticorps chez des personnes immunodéprimées après vaccination contre le COVID-19 avec les vaccins Pfizer-BioNTech et Moderna. Clinical Infectious Diseases En Suisse, les deux vaccins COVID-19 de Pfizer-BioNTech et Moderna ont été autorisés en décembre 2020 et janvier 2021. Les deux vaccins ont été testés dans le cadre d’études d’autorisation impliquant plusieurs dizaines de milliers de […]